Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors

• Published in: Autoimmunity reviews Vol. 13; no. 2; pp. 197 - 205
• Main Authors: Samson, Maxime, Puéchal, Xavier, Devilliers, Hervé, Ribi, Camillo, Cohen, Pascal, Bienvenu, Boris, Ruivard, Marc, Terrier, Benjamin, Pagnoux, Christian, Mouthon, Luc, Guillevin, Loïc
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier 01-02-2014
• Subjects: Adult; Aged; Allergy and Immunology; Female; Follow-Up Studies; Glucocorticoids - therapeutic use; Humans; Immunology; Immunosuppressive Agents - therapeutic use; Life Sciences; Male; Microscopic Polyangiitis - drug therapy; Microscopic Polyangiitis - mortality; Microscopic Polyangiitis - pathology; Middle Aged; Polyarteritis Nodosa - drug therapy; Polyarteritis Nodosa - mortality; Polyarteritis Nodosa - pathology; Randomized Controlled Trials as Topic; Recurrence; Survival Analysis; Microscopic polyangiitis; Long-term follow-up; Sequelae; Polyarteritis nodosa; ANCA; Relapses
• ISSN: 1568-9972; 1873-0183
• DOI: 10.1016/j.autrev.2013.10.001

Abstract The purpose of this study was to assess the long-term outcomes of patients with polyarteritis nodosa (PAN) or microscopic polyangiitis (MPA) without Five-Factor Score (FFS)-defined poor-prognosis factors (FFS = 0) and enrolled in a prospective clinical trial. Patients were followed (2005–2012) under routine clinical care in an extended study and data were recorded prospectively. Long-term survival, disease-free survival (DFS), relapses, therapeutic responses and sequelae were analyzed. Mean ± SD follow-up was 98.2 ± 41.9 months. After having initially received glucocorticoids (GC) alone, according to the study protocol, 82% (97/118) patients achieved remission but 18% (21/118) required ≥ 1 immunosuppressant(s) (IS) before 19/21 achieved remission. Two patients died before entering remission. After remission, 53% (61/116) patients relapsed 25.6 ± 27.9 months after starting treatment. The 5- and 8-year overall survival rates were 93% and 86%, respectively, with no difference between PAN and MPA, and between relapsers and nonrelapsers. DFS was shorter for MPA than PAN patients ( P = 0.02). Throughout follow-up, 47% of patients required ≥ 1 IS. At the last follow-up visit, 44% were still taking GC and 15% IS. The mean vasculitis damage index score was 1.9 ± 1.9; the most frequent sequelae were peripheral neuropathy, hypertension and osteoporosis. For PAN or MPA patients without poor-prognosis factors at diagnosis and treated initially with GC alone, long-term survival was excellent. However, relapses remained frequent, requiring IS introduction for nearly half of the patients. To lower the frequencies of relapses and sequelae remains a challenge for FFS = 0 PAN and MPA patients.